AXA Framlington Biotech Fund R Accumulation GBP/  GB0031007254  /

The aim of this Fund is to provide long-term capital growth over a period of 5 years or more. The Fund invests in shares of listed companies, principally (meaning at least 80% of its assets) in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Manager selects shares based upon analysis of a company"s financial status, quality of its management, expected profitability and prospects for growth. The Manager has full discretion to select investments for the Fund in line with the above investment policy and in doing so may take into consideration the NASDAQ Biotechnology index. The NASDAQ Biotechnology index is designed to measure the performance of NASDAQ stocks in the biotechnology sector. This index best represents a core component of the Managers" investment universe. The Fund may also invest in other transferable securities and units in collective investment schemes. The Fund may use derivatives for Efficient Portfolio Management. Use may be made of borrowing, cash holdings, hedging and other investment techniques permitted in the applicable Financial Conduct Authority rules.

The aim of this Fund is to provide long-term capital growth over a period of 5 years or more.